Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Archives of Pathology & Laboratory Medicine

• Publication date

  2013-01-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.5858/arpa.2012-0635-OAPMID 23289761
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2012

  2012cited by this paper
• A 6-Antibody Panel for the Classification of Lung Adenocarcinoma Versus Squamous Cell Carcinoma

  2012cited by this paper
• Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray.

  2012cited by this paper
• Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung.

  2012cited by this paper
• The role of P63 in cancer, stem cells and cancer stem cells

  2011cited by this paper
• Subclassification of Non-small Cell Lung Carcinomas Lacking Morphologic Differentiation on Biopsy Specimens: Utility of an Immunohistochemical Panel Containing TTF-1, Napsin A, p63, and CK5/6

  2011cited by this paper
• Rapid Multiplex Immunohistochemistry Using the 4-antibody Cocktail YANA-4 in Differentiating Primary Adenocarcinoma From Squamous Cell Carcinoma of the Lung

  2011cited by this paper
• Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens.

  2011cited by this paper
• Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate.

  2011cited by this paper
• A study of immunohistochemical differential expression in pulmonary and mammary carcinomas

  2010cited by this paper
• A Single Institution-Based Retrospective Study of Surgically Treated Bronchioloalveolar Adenocarcinoma of the Lung: Clinicopathologic Analysis, Molecular Features, and Possible Pitfalls in Routine Practice

  2010cited by this paper
• Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.

  2010cited by this paper
• Genome-Wide Mapping Indicates That p73 and p63 Co-Occupy Target Sites and Have Similar DNA-Binding Profiles In Vivo

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Intricacies of Bevacizumab-Induced Toxicities and Their Management

  2009cited by this paper
• The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung.

  2009influential reference
• A novel five-antibody immunohistochemical test for subclassification of lung carcinoma

  2009cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008influential reference
• Cathepsin H and napsin A are active in the alveoli and increased in alveolar proteinosis

  2008cited by this paper
• Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung.

  2008cited by this paper
• Cytoplasmic immunoreactivity of thyroid transcription factor-1 (clone 8G7G3/1) in hepatocytes: true positivity or cross-reaction?

  2007cited by this paper
• Desmoglein 3 as a prognostic factor in lung cancer.

  2007cited by this paper
• New molecularly targeted therapies for lung cancer.

  2007cited by this paper
• A five-gene signature and clinical outcome in non-small-cell lung cancer.

  2007cited by this paper
• Napsin A (TA02) is a useful alternative to thyroid transcription factor‐1 (TTF‐1) for the identification of pulmonary adenocarcinoma cells in pleural effusions

  2007cited by this paper
• p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity

  2007cited by this paper
• A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer

  2006cited by this paper
• Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study.

  2006cited by this paper
• TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material

  2006cited by this paper
• Predicting Survival within the Lung Cancer Histopathological Hierarchy Using a Multi-Scale Genomic Model of Development

  2006cited by this paper
• Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003.

  2005cited by this paper
• Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs.

  2005cited by this paper
• Expression of TTF‐1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade

  2004cited by this paper
• p63 expression in assessment of bronchioloalveolar proliferations of the lung

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• p63 Expression in Lung Carcinoma: A Tissue Microarray Study of 408 Cases

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Molecular classification and molecular genetics of human lung cancers.

  2004cited by this paper
• Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma

  2003cited by this paper
• Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray

  2003cited by this paper
• Significance of p63 amplification and overexpression in lung cancer development and prognosis.

  2003cited by this paper
• Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study.

  2003cited by this paper
• Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma.

  2003cited by this paper
• Immunohistochemical Detection of Thyroid Transcription Factor-1, Thyroglobulin, and Calcitonin in Canine Normal, Hyperplastic, and Neoplastic Thyroid Gland

  2002cited by this paper
• Expression of Thyroid Transcription Factor-1 in Normal and Neoplastic Lung Tissues

  2002cited by this paper
• Suprabasal Desmoglein 3 Expression in the Epidermis of Transgenic Mice Results in Hyperproliferation and Abnormal Differentiation

  2002cited by this paper
• Thyroid Transcription Factor-1: A Review

  2002cited by this paper
• Taking Advantage of Basic Research: p63 Is a Reliable Myoepithelial and Stem Cell Marker

  2002cited by this paper
• Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids.

  2002cited by this paper
• Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases

  2002cited by this paper
• p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?

  2002cited by this paper
• Diversity of gene expression in adenocarcinoma of the lung

  2001cited by this paper
• Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category

  2000cited by this paper
• Expression of thyroid transcription factor‐1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites

  2000cited by this paper
• Thyroid Transcription Factor-1 Is Expressed in Extrapulmonary Small Cell Carcinomas but Not in Other Extrapulmonary Neuroendocrine Tumors

  2000cited by this paper
• Thyroid transcription factor‐1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B

  2000cited by this paper
• Molecular map of the desmosomal plaque.

  1999cited by this paper
• p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development

  1999cited by this paper
• Structure and interactions of desmosomal and other cadherins.

  1992cited by this paper

• Utility of Immunohistochemistry in the Diagnosis of Pleuropulmonary and Mediastinal Cancers: A Review and Update.

  2023cites this paper
• Characterization of Desmoglein 3 (DSG3) as a Sensitive and Specific Marker for Esophageal Squamous Cell Carcinoma

  2022cites this paper
• Clinicopathological correlation of p40/TTF1 co-expression in NSCLC and review of related literature

  2022cites this paper
• Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma.

  2022cites this paper
• Real-World Diagnostic Accuracy and Use of Immunohistochemical Markers in Lung Cancer Diagnostics

  2021cites this paper
• An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin

  2020cites this paper
• Analysis of PAX8 immunohistochemistry in lung cancers: a meta-analysis

  2020cites this paper
• ROLE OF VARIOUS IHC MARKERS IN CLASSIFICATION OF LUNG CARCINOMA ON ENDOBRONCHIAL BIOPSIES.

  2020cites this paper
• Triple marker composed of p16, CD56, and TTF1 shows higher sensitivity than INSM1 for diagnosis of pulmonary small cell carcinoma: proposal for a rational immunohistochemical algorithm for diagnosis of small cell carcinoma in small biopsy and cytology specimens.

  2019cites this paper
• Chromogenic immunohistochemical quadruplex provides accurate diagnostic differentiation of non-small cell lung cancer.

  2019cites this paper
• P40 expression in small cell lung cancer: The presence of p40‐positive cells does not always indicate squamous differentiation

  2019cites this paper
• Transformation to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma.

  2018cites this paper
• Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.

  2018cites this paper
• Neuroendocrine Pulmonary Tumors of Low, Intermediate and High Grade: Anatomopathological Diagnosis—Prognostic and Predictive Factors

  2018cites this paper
• Classic Anatomic Pathology and Lung Cancer

  2018cites this paper
• P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens.

  2018cites this paper
• Lung

  2018cites this paper
• TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.

  2017cites this paper
• Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.

  2017cites this paper
• p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category

  2017cites this paper
• Pleural fluid cytology samples in cases of suspected lung cancer: An experience from a tertiary care centre

  2017cites this paper
• Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.

  2017cites this paper
• Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells

  2016cites this paper
• Napsin A/p40 antibody cocktail for subtyping non‐small cell lung carcinoma on cytology and small biopsy specimens

  2016cites this paper
• A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.

  2016cites this paper
• Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung

  2016cites this paper
• Classification and Pathology of Lung Cancer.

  2016cites this paper
• The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas

  2016influential citation
• Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.

  2016cites this paper
• Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations.

  2016cites this paper
• Triple SILAC quantitative proteomic analysis reveals differential abundance of cell signaling proteins between normal and lung cancer-derived exosomes.

  2016cites this paper
• Folate Receptor α Expression Level Correlates With Histologic Grade in Lung Adenocarcinoma.

  2016cites this paper
• Unknown Primary/Undifferentiated Neoplasm

  2015cites this paper
• Ancillary Immunohistochemical Techniques for the Subclassification of Non-small Cell Lung Cancer

  2015cites this paper
• Identification of immunohistochemical markers for distinguishing lung adenocarcinoma from squamous cell carcinoma.

  2015cites this paper
• Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.

  2015cites this paper
• A Comparative Study of International Classification forLung Cancer and WHO Classification in Histological Diagnosis of Lung Cancer in Small Biopsies

  2015cites this paper
• TTF-1 [ SPT 24 ] Staining Specificity in Lung Adenocarcinoma vs . Lung Squamous Cell Carcinoma is Markedly Improved with Titer Optimization and Cut-Off Values

  2015cites this paper
• The minimal carcinoma triple stain is superior to commercially available multiplex immunohistochemical stains: breast triple stain and LC/DC breast cocktail.

  2015cites this paper
• An immunohistochemical analysis of a newly developed, mouse monoclonal p40 (BC28) antibody in lung, bladder, skin, breast, prostate, and head and neck cancers.

  2014cites this paper
• Napsin A expression in small cell carcinoma of the lung: a cytologic study with review of differentials.

  2014cites this paper
• Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India

  2014cites this paper
• Immunohistochemistry in undifferentiated neoplasm/tumor of uncertain origin.

  2014cites this paper
• The High Diagnostic Accuracy of Combined Test of Thyroid Transcription Factor 1 and Napsin A to Distinguish between Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta-Analysis

  2014cites this paper
• Utility of immunohistochemistry in the diagnosis of pleuropulmonary and mediastinal cancers: a review and update.

  2014cites this paper
• Usefulness of GATA3 and p40 immunostains in the diagnosis of metastatic urothelial carcinoma in cytology specimens

  2014cites this paper
• REALITIES AND PERSPECTIVES IN EARLY DIAGNOSIS OF LUNG CANCER IN GORJ COUNTY Scientific coordinator : Professor

  2014cites this paper
• The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.

  2014influential citation
• Does Immunohistochemistry Affect Response to Therapy and Survival of Inoperable Non–Small Cell Lung Carcinoma Patients? A Survey of 145 Stage III-IV Consecutive Cases

  2014cites this paper
• Molecular testing in lung cancer: Fine‐needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication

  2014cites this paper
• The proposed new classification of pulmonary adenocarcinoma and the conservation of small tissue samples for testing.

  2013cites this paper
• Atlas of Fine Needle Aspiration Cytology

  2013cites this paper